It's not just marketing.. dose monitoring and treatment efficacy in traditional chemotherapy has been an ongoing problem since the beginning. This is especially problematic when the basis for chemotherapy is, well, killing cells. Current imaging techniques are ill suited for continual monitoring - either because of cost or further radiation damage.
- Forums
- ASX - By Stock
- Siemens and Sirtex
It's not just marketing.. dose monitoring and treatment efficacy...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
12.8¢ |
Change
0.003(2.00%) |
Mkt cap ! $54.11M |
Open | High | Low | Value | Volume |
12.5¢ | 13.5¢ | 12.5¢ | $100.8K | 776.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 710395 | 12.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.0¢ | 424086 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 710395 | 0.125 |
2 | 538500 | 0.120 |
2 | 12877 | 0.097 |
2 | 15000000 | 0.096 |
2 | 355609090 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.130 | 387472 | 2 |
0.135 | 1664647 | 5 |
0.140 | 765214 | 13 |
0.145 | 405968 | 3 |
0.150 | 126060 | 11 |
Last trade - 15.58pm 21/06/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online